Westport announces $50M at-the-market equity offering program 11/09 WPRT Westport Fuel Systems announced that the company has established an at-the-market equity offering program that allows the company to issue up to $50M of common shares from treasury to the public from time to time, at the company's discretion and subject to regulatory requirements. Sales of Common Shares through the ATM Program will be made pursuant to the terms of an Equity Distribution Agreement dated November 9, entered into among the company, RBC Dominion Securities, RBC Capital Markets, Oppenheimer & Co. and H.C. Wainwright & Co. Do not believe they have executed this yet... Stk was $2 Nov 9!!!!!! NOW->$7.75!!!!!! Why is nobody talking about this. They could equity offer at any time....
Vir Biotechnology, Inc. (VIR)... Something cooking? This is a Vax player I have not looked into. In the past few days the stk has looked strong. $43.37+4.41 (+11.32%) <----------- At close: January 20 4:00PM EST 46.00+2.63 (6.06%)<------------------ Before hours:8:41AM EST
yesterday... Vir Biotechnology price target raised to $125 from $100 at H.C. Wainwright 06:24 VIR H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Vir Biotechnology to $125 from $100 and keeps a Buy rating on the shares. VIR-7831 is on track to emerge as a "best-in-class" SARS-CoV-2 antiviral treatment, Trucchio tells investors in a research note. The analyst continues to believe a "robust" post-pandemic COVID-19 antiviral market could emerge with VIR-7831 and next-gen antibodies gaining a commanding share.
+ GNOG + TX WATCHING THE BIDEN SWEARING IN AND THEY SAID EVERYONE MALE WAS WEARING RALPH LAUREN... APPEARS TO BE BIDEN'S DESIGNER I TURNED TO MY WIFE AND SAID MAYBE RL IS AN INVESTMENT..... --Ralph Lauren price target raised to $127 from $75 at Deutsche Bank 07:37 RL Deutsche Bank analyst Paul Trussell raised the firm's price target on Ralph Lauren to $127 from $75 and keeps a Hold rating on the shares. COVID has been a "meaningful positive catalyst" for margin trajectory as it forced retailers to make decisions about organizational structure, real estate, and pace of digital investments while also experiencing reduced competition and an opportunity to reset promotional activity and inventory level, Trussell tells investors in a research note. --Upland Software price target raised to $57 from $52 at Canaccord --Here we go again... SOS-->SOS Limited to acquire 15645 mining rigs for $20M » Fucking sneaky earlierthey did this-> SOS Limited files $300M mixed securities shelf XBiotech announces True Human therapy found to target emerging strain 08:28 XBIT XBiotech announces that its COVID-19 candidate True Human antibody therapy may also be used for treating the COVID-19 mutant virus that recently emerged in the UK and is now rapidly spreading across the US. The mutant COVID-19 virus has alterations to the spike protein that reportedly make the virus more contagious, and these mutations might also enable the virus to escape existing vaccines or therapies. XBiotech's candidate therapy specifically targets the so-called spike protein of the virus and potently neutralizes the virus' ability to infect cells. The company analyzed its candidate COVID-19 therapy for its ability to bind the spike protein of the mutant COVID-19 virus and was found to have the same high affinity for spike protein of both the original COVID-19 and mutant COVID-19 viruses. These findings provide quick and convincing evidence that XBiotech's candidate True Human therapy, which was potently effective in neutralizing the original strain of COVID-19, could be expected to be similarly effective at neutralizing the mutant strain of the virus. The new mutant COVID-19 virus has undergone changes that include small differences in the so-called spike protein of the virus. Scientists at XBiotech used a state-of-the-art method employing bio-layer interferometry to analyze binding of its COVID-19 True Human antibody to the spike protein of the mutant strain. These studies showed the antibody bound to the mutant spike protein with same high affinity as it does to the original COVID-19 virus. The Company previously announced that its candidate True Human therapy for COVID-19-isolated from an actual patient that had recovered from the infection-was found to neutralize the virus at concentrations about four-times better than antibodies currently FDA approved under emergency use authorization. The higher rate of transmission of the mutant COVID-19 virus means that it could quickly become the dominant form of the virus in the US. The CDC in fact predicts the new variant will be the main cause of COVID infections in the USA by March, 2021. A therapy that could be used to treat both COVID-19 and the mutant strains of the virus could be of crucial importance as the mutant virus spreads. The Company has engineered production capable cell lines and is prepared to establish manufacturing processes for clinical development as necessary.
<<WATCH>> CLNE-- WPRT-- ARRY-- XONE-- ONEM-- GNOG-- TX-- SOS-- UPLD-- XBIT-- Golden Nugget Online initiated with a Buy at Benchmark 01/13 GNOG, LCA Benchmark analyst Mike Hickey initiated coverage of Golden Nugget Online Gaming (GNOG) with a Buy rating and $27 price target following the recent closing of its deal to come public via a merger with the Landcadia Holdings II (LCA) SPAC. Golden Nugget has a "leading brand and market share" in mobile online casinos as well as an early position in online sports betting, said Hickey, who views both markets as "potentially massive and accelerating."
IBD STOCK OF THE DAY One Medical, IBD Stock Of The Day, Breaks Out On Covid Vaccines, Analyst Pick Licensing 04:27 PM ET 01/19/2021 1Life Healthcare ONEM $ 47.71 $5.0311.79%139% IBD Stock Analysis Clears 44.59 buy point in heavy volume Relative strength line clears short-term high, nears record Revenue growth accelerated to 46% in latest quarter Composite Rating 28/99 Industry Group Ranking 166/197 Emerging Pattern Cup with Handle-- ALSO CALLED THE ANASTASSIA CURVE! One Medical brand clinic operator1Life Healthcare(ONEM) is theIBD Stock Of The Dayas ONEM stock broke out past a buy point and to record high Tuesday. The Covid vaccine rollout and a "top idea" call from a Wall Street analyst are both giving the fast-growing 2020 IPO a shot of momentum. Volume 0% On Tuesday, JPMorgan Chase health care analyst Lisa Gill called ONEM stock her top idea for 2021 among small and midcap companies. Gill also toutedTeladoc(TDOC) as her top technology play andCVS Health(CVS) as the most compelling value play. One Medical Investor Presentation Gill's ONEM stock calls follow last week's JPMorgan Healthcare Conference at which she hosted presentations by One Medical CEO Amir Rubin, among others. Gill noted during the Jan. 12 presentation that a 60 Net Promoter Score, the net share of consumers likely to recommend a service, is good in health care. She called One Medical's 90 rating "off the charts." Rubin explained that One Medical's popularity comes from seamlessly coordinating care on behalf of members through digital channels. That includes reminders that it's time for a cancer screening, to scheduling appointments and sharing records with specialists at its local health network partners. One Medical's role is " to own that complexity on behalf of consumers," Rubin said. One Medical's role in Covid vaccinations will have an impact on revenue, but other effects of serving the community are more meaningful. Rubin noted that anyone can seek their vaccination through One Medical, not just members. "Coming out of that, consumers get exposure to One Medical," as do employers, Rubin said. He added that One Medical has been serving a number of schools and universities. In a discussion of telehealth, Rubin noted that One Medical has made its digital services available even in markets where it doesn't have clinics. The reason: The company is "now starting to engage with multimarket employers," Rubin said, expanding its market opportunity. On Jan. 8, Piper Sandler analyst Sean Wieland raised his ONEM stock price target to 51 from 44, citing his firm's proprietary app download analysis. Wieland noted 38,500 One Medical app downloads in Q4. That compares to One Medical's guidance of 19,000 to 29,000 new members in the quarter. ONEM Stock Analysis ONEM stock surged 12% to 47.71 in Tuesday's stock market action, breaking out from a 27-weekcup-with-handlebase, according to aMarketSmith analysis. Thebuy pointis 10 cents above the handle high of 44.49 on Jan. 4. The buy zone runs through 46.82, 5% above the buy point. Volume was heavy on the ONEM stock breakout. The One Medical stock base was 43% deep, which is more than investors would typically like to see. But deep bases can work and recent IPOs are often more volatile. One Medical stock'srelative strength line, the blue line in the charts provided, hasn't quite cleared its July 10 peak. That came amid a failed breakout attempt. ONEM stock may have suffered as the summer Covid wave escalated, since that's a headwind for in-office fee-for-service visits. One Medical Business San Francisco-based One Medical had 511,000 members at the end of Q3, up 29% from a year ago. Revenue grew 46% to $101.7 million, the best gain in at least five quarters. Rubin told the JPMorgan conference that membership revenue accounts for 19% of the total. That reflects employer fees on behalf of workers and $199 annual payments by individuals. The rest is split between fees for in-office or telehealth visits and payments from health network partners. One Medical had 103 clinics at the end of Q3, up 20 year-to-date, in 12 cities. It plans to expand to five more markets by the end of 2021. The company reported an adjusted EBITDA profit of $3.5 million in Q3 but management said that was due to pent-up demand, forecasting a Q4 loss. Amazon(AMZN) is seen as a potential competitor long term as it begins to expand clinics beyond its own employees.
WPRT LOOKS ACTIVE IN PRE--- I LOOKED UP TECHNICALS - Chart Events Bearishpattern detected Hanging Man<--? THAT DOESN'T SOUND GOOD Westport Fuel Systems Inc. (WPRT)-- 7.11+0.14 (+2.01%) At close: January 20 4:00PM EST $7.92+0.81 (11.39%)<--------------- Before hours:9:15AM EST
This is probably going to surprise you guys but of these sexy gambling and bio and other names moving in the pre--the one that is most appealing to me is UPLAND Software. I think it's a good name and a good symbol. I have noticed it in the past and wondered what they did and they bought someone yesterday. They paid $25 mil for $9 mil annually..... so the deal pays for itslef in 3 years! Jan. 20, 2021 9:41 AM ET Upland Software, Inc. (UPLD) Upland Software (UPLD +2.6%) has acquired Second Street Media, a leading audience engagement cloud software platform for $25.4M in cash at closing, paid out of cash on hand, and a $5M cash holdback payable in 12 months. Upland will integrate Second Street into its Customer Experience Management product suite, which includes email and mobile messaging solutions. Upland expects the acquisition to generate annual revenue of ~$9.4M, of which all is recurring. It is also expected that Second Street will generate at least $4.2M in adj. EBITDA annually once fully integrated. The acquisition will be immediately accretive to Upland’s Adj. EBITDA/share.